Show simple item record

dc.contributor.authorKenney-Herbert, Een_US
dc.contributor.authorAl-Mayhani, Ten_US
dc.contributor.authorPiccirillo, SGMen_US
dc.contributor.authorFowler, Jen_US
dc.contributor.authorSpiteri, Ien_US
dc.contributor.authorJones, Pen_US
dc.contributor.authorWatts, Cen_US
dc.date.accessioned2018-07-16T15:07:56Z
dc.date.issued2015-07en_US
dc.identifier.citationStem cells translational medicine, 2015, 4 (7), pp. 822 - 831en_US
dc.identifier.issn2157-6564en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2077
dc.identifier.eissn2157-6580en_US
dc.identifier.doi10.5966/sctm.2014-0047en_US
dc.description.abstract: Recent research has focused on the hypothesis that the growth and regeneration of glioblastoma (GB) is sustained by a subpopulation of self-renewing stem-like cells. This has led to the prediction that molecular markers for cancer stem cells in GB may provide a treatment target. One candidate marker is CD15: we wanted to determine if CD15 represented a credible stem cell marker in GB. We first demonstrated that CD15-positive (CD15+) cells were less proliferative than their CD15-negative (CD15-) counterparts in 10 patient GB tumors. Next we compared the proliferative activity of CD15+ and CD15- cells in vitro using tumor-initiating primary GB cell lines (TICs) and found no difference in proliferative behavior. Furthermore, TICs sorted for CD15+ and CD15- were not significantly different cytogenetically or in terms of gene expression profile. Sorted single CD15+ and CD15- cells were equally capable of reconstituting a heterogeneous population containing both CD15+ and CD15- cells over time, and both CD15+ and CD15- cells were able to generate tumors in vivo. No difference was found in the phenotypic or genomic behavior of CD15+ cells compared with CD15- cells from the same patient. Moreover, we found that in vitro, cells were able to interconvert between the CD15+ and CD15- states. Our data challenge the utility of CD15 as a cancer stem cell marker.The data from this study contribute to the ongoing debate about the role of cancer stem cells in gliomagenesis. Results showed that CD15, a marker previously thought to be a cancer stem-like marker in glioblastoma, could not isolate a phenotypically or genetically distinct population. Moreover, isolated CD15-positive and -negative cells were able to generate mixed populations of glioblastoma cells in vitro.en_US
dc.formatPrint-Electronicen_US
dc.format.extent822 - 831en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleCD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population.en_US
dc.typeJournal Article
dcterms.dateAccepted2015-02-23en_US
rioxxterms.versionofrecord10.5966/sctm.2014-0047en_US
rioxxterms.licenseref.startdate2015-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfStem cells translational medicineen_US
pubs.issue7en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.publication-statusPublisheden_US
pubs.volume4en_US
pubs.embargo.termsNot knownen_US
icr.researchteamEvolutionary Genomics & Modellingen_US
dc.contributor.icrauthorSpiteri Sagastume, Mariaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/